Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> MMP
Overview
Product name
ADAM33 peptide (Aminoterminal end)
See all ADAM33 products (4) ...
Protein description
Synthetic peptide ADAM33. (Note: the amino acid sequence is proprietary) This peptide was used as an immunogen for ab39191 - ADAM33 antibody - Aminoterminal end.
Properties
Purity
>95% by SDS-PAGE
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage buffer
Preservative: None
Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75
Concentration
Concentration information loading...
Research areas
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Metalloprotease >> ADAMs
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> ADAM Protein Family
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> MMP
Applications
Show applications key
Our Abpromise guarantee covers the use of ab41228 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA
WB
Application notes
ELISA: Use at an assay dependent dilution. WB: Use at an assay dependent dilution. This peptide can be used with studies using ab39191. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
Protein info
Tissue specificity
Expressed in all tissues, except liver, with high expression in placenta, lung, spleen and veins.
Involvement in disease
Genetic variations in ADAM33 are associated with susceptibility to asthma (ASTHMA) [MIM:600807]. The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with weezing due to spasmodic contraction of the bronchi.
Sequence similarities
Contains 1 disintegrin domain.
Contains 1 EGF-like domain.
Contains 1 peptidase M12B domain.
Domain
The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Post-translational
modifications
The precursor is cleaved by a furin endopeptidase.
Cellular localization
Membrane.
Target information above from: UniProt accessionQ9BZ11
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
References for ADAM33 peptide (Aminoterminal end) (ab41228)
ab41228 has not yet been referenced specifically in any publications.
Publishing research using ab41228? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"